載入中
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
前收盤價
US$0.4452
−US$0.0351 · -7.31%
盤中時間採用ET。市場資料可能有所延遲。
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
日內區間
目前US$0.4452
52週區間
目前US$0.4452
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
60
合理估值
情緒
53
多空交錯
風險
73
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
日內區間
目前US$0.4452
52週區間
目前US$0.4452
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 279萬 USD | 22.6萬 USD | 22.6萬 USD | 22.6萬 USD | 22.6萬 USD |
| 銷貨成本 | — | 1.2萬 USD | — | — | — |
| 毛利 | 279萬 USD | 21.4萬 USD | 22.6萬 USD | 22.6萬 USD | 22.6萬 USD |
| 研究與開發 | 1214.3萬 USD | 1.3億 USD | 1143萬 USD | 1140.6萬 USD | 729.7萬 USD |
| 銷售、一般及管理費用 | 852.2萬 USD | 1228.9萬 USD | 909.4萬 USD | 844.7萬 USD | 942.5萬 USD |
| 營業費用 | 2066.5萬 USD | 4956.2萬 USD | 2052.4萬 USD | 1985.3萬 USD | 1672.2萬 USD |
| 折舊和攤銷 | 6.1萬 USD | 1.2萬 USD | 1.6萬 USD | 1.4萬 USD | 1.4萬 USD |
| 營業利益 | −1787.5萬 USD | −4934.8萬 USD | −2029.8萬 USD | −1962.7萬 USD | −1649.6萬 USD |
| 淨利 | 917萬 USD | −5467.4萬 USD | −1894.8萬 USD | −1896.4萬 USD | −1616.3萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1.00
上漲空間 124.62%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年9月23日 | 1:25 | — | — |
股票分割 | 2021年5月21日 | 1:15 | — | — |
股票分割 | 2018年9月26日 | 1:15 | — | — |
股票分割 | 2016年6月1日 | 1:10 | — | — |
已生效 2024年9月23日
1:25
已生效 2021年5月21日
1:15
已生效 2018年9月26日
1:15
已生效 2016年6月1日
1:10
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
